Pixium on 31 March reported positive 18-month follow-up data from its European feasibility study (PRIMA-FS) on the Prima 2 system in patients with advanced atrophic dry age-related macular degeneration (Dry-AMD). The data showed continued safety and improvements of between three and seven lines on the Landolt C visual acuity (VA) scale versus baseline. The VA improvements show further evidence of clinical activity and reinforce our confidence in the programme as the firm works towards a filin
06 Apr 2020
Pixium Vision - Prima 2 18-month data shows strong promise
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pixium Vision - Prima 2 18-month data shows strong promise
Pixium on 31 March reported positive 18-month follow-up data from its European feasibility study (PRIMA-FS) on the Prima 2 system in patients with advanced atrophic dry age-related macular degeneration (Dry-AMD). The data showed continued safety and improvements of between three and seven lines on the Landolt C visual acuity (VA) scale versus baseline. The VA improvements show further evidence of clinical activity and reinforce our confidence in the programme as the firm works towards a filin